Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 14, 2026

Daily Signals

2493 companies scored · 2026-10-14 run in progress: 1149 of ~5379 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-14 Cut-offs from the 2026-10-13 run
Companies scored 2493 IC ≥ 0 · market cap ≥ $100M
Median forecast +0.26% Alpha · 90D
Long–short spread +3.95% Strong Buy minus Strong Sell, mean
Median IC 0.29 Spearman · 90D
Rating changes ▲ 47 ▼ 58 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

287 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
101 XERSXeris Biopharma Holdings, Inc. Life Sciences 0.20 $1.9B Unlock rating and forecasts
102 URGNUroGen Pharma Ltd. Life Sciences 0.44 $1.9B Unlock rating and forecasts
103 XNCRXencor Inc Life Sciences 0.46 $1.9B Unlock rating and forecasts
104 MLYSMineralys Therapeutics, Inc. Life Sciences 0.28 $1.9B Neutral +0.37% -0.30% ·
105 TRVITrevi Therapeutics, Inc. Life Sciences 0.32 $1.8B Neutral +0.23% +0.50% ·
106 SRPTSarepta Therapeutics, Inc. Life Sciences 0.24 $1.8B Unlock rating and forecasts
107 XTLBXTL BIOPHARMACEUTICALS LTD Life Sciences 0.15 $1.8B Neutral +0.28% +0.01% ·
108 AGIOAGIOS PHARMACEUTICALS, INC. Life Sciences 0.02 $1.8B Neutral -0.10% +0.01% ·
109 SEPNSepterna, Inc. Life Sciences 0.06 $1.8B Unlock rating and forecasts
110 ZBIOZenas BioPharma, Inc. Life Sciences 0.19 $1.7B Unlock rating and forecasts
111 MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. Life Sciences 0.62 $1.7B Unlock rating and forecasts
112 NTLAIntellia Therapeutics, Inc. Life Sciences 0.48 $1.7B Unlock rating and forecasts
113 OCULOCULAR THERAPEUTIX, INC Life Sciences 0.13 $1.7B Neutral +0.50% -0.48% ·
114 NUVBNuvation Bio Inc. Life Sciences 0.35 $1.7B Neutral +0.37% +0.46% ·
115 ANIPANI PHARMACEUTICALS INC Life Sciences 0.46 $1.6B Unlock rating and forecasts
116 GENBGenerate Biomedicines, Inc. Life Sciences 0.10 $1.6B Unlock rating and forecasts
117 STOKStoke Therapeutics, Inc. Life Sciences 0.40 $1.6B Unlock rating and forecasts
118 CMPSCOMPASS Pathways plc Life Sciences 0.14 $1.5B Unlock rating and forecasts
119 ETONEton Pharmaceuticals, Inc. Life Sciences 0.13 $1.5B Unlock rating and forecasts
120 INVAInnoviva, Inc. Life Sciences 0.42 $1.5B Unlock rating and forecasts
121 PAHCPHIBRO ANIMAL HEALTH CORP Life Sciences 0.47 $1.5B Neutral -0.11% -0.13% ·
122 MAZEMaze Therapeutics, Inc. Life Sciences 0.30 $1.5B Unlock rating and forecasts
123 RAREUltragenyx Pharmaceutical Inc. Life Sciences 0.36 $1.5B Unlock rating and forecasts
124 PCRXPacira BioSciences, Inc. Life Sciences 0.30 $1.4B Neutral +0.21% -0.07% ·
125 RAPPRapport Therapeutics, Inc. Life Sciences 0.12 $1.4B Unlock rating and forecasts
126 CBIOGYRE THERAPEUTICS, INC. Life Sciences 0.12 $1.4B Unlock rating and forecasts
127 IMCRImmunocore Holdings plc Life Sciences 0.12 $1.4B Unlock rating and forecasts
128 OMEROMEROS CORP Life Sciences 0.46 $1.4B Neutral -0.10% +0.27% ·
129 QUREuniQure N.V. Life Sciences 0.35 $1.4B Neutral +0.23% -0.05% ·
130 TSHATaysha Gene Therapies, Inc. Life Sciences 0.20 $1.3B Unlock rating and forecasts
131 ANABANAPTYSBIO, INC Life Sciences 0.56 $1.3B Neutral -0.05% +0.33% ·
132 NKTRNEKTAR THERAPEUTICS Life Sciences 0.35 $1.3B Unlock rating and forecasts
133 REPLReplimune Group, Inc. Life Sciences 0.38 $1.2B Unlock rating and forecasts
134 TYRATyra Biosciences, Inc. Life Sciences 0.26 $1.2B Unlock rating and forecasts
135 GHRSGH Research PLC Life Sciences 0.05 $1.2B Unlock rating and forecasts
136 AMPHAmphastar Pharmaceuticals, Inc. Life Sciences 0.47 $1.1B Neutral -0.11% -0.02% ·
137 OPKOPKO HEALTH, INC. Life Sciences 0.04 $1.0B Unlock rating and forecasts
138 MNKDMANNKIND CORP Life Sciences 0.57 $981M Unlock rating and forecasts
139 MGTXMeiraGTx Holdings plc Life Sciences 0.10 $955M Neutral +0.18% -0.46% ·
140 IMTXImmatics N.V. Life Sciences 0.26 $916M Neutral +0.38% +0.35% ·
141 QDELQuidelOrtho Corp Life Sciences 0.20 $909M Neutral -0.10% +0.06% ·
142 CGEMCullinan Therapeutics, Inc. Life Sciences 0.50 $907M Unlock rating and forecasts
143 RIGLRIGEL PHARMACEUTICALS INC Life Sciences 0.20 $881M Unlock rating and forecasts
144 ANROAlto Neuroscience, Inc. Life Sciences 0.19 $867M Unlock rating and forecasts
145 CYRXCryoport, Inc. Life Sciences 0.39 $858M Unlock rating and forecasts
146 ALMSALUMIS INC. Life Sciences 0.49 $849M Unlock rating and forecasts
147 GLUEMonte Rosa Therapeutics, Inc. Life Sciences 0.23 $844M Unlock rating and forecasts
148 ABUSArbutus Biopharma Corp Life Sciences 0.03 $813M Neutral +0.16% +0.14% ·
149 DNAGinkgo Bioworks Holdings, Inc. Life Sciences 0.23 $792M Unlock rating and forecasts
150 CRVSCorvus Pharmaceuticals, Inc. Life Sciences 0.33 $792M Unlock rating and forecasts
101–150 of 287 Previous Next
Since the previous run

Rating changes

▲ 47▼ 58
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.